FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to pharmacy and medicine, and concerns a composition, a method and a kit which enable a controlled release of octreotide, e.g. octreotide acetate in an individual. The composition contains a preparation containing octreotide basically enclosed in a hydrophilic polymer specified in polyurethane polymers and methacrylate polymers; it is effective for providing octreotide release at a rate of 30 mcg to 800 mcg a day for six months in vivo, wherein the hydrophilic polymer, but not the preparation, additionally contains a releasing substance with molecular weight of at least approximately 1,000 Dalton, wherein the preparation contains octreotide 40 to 120 mg, and the releasing substance is specified in a group consisting of Brij 35 (polyoxyethylene lauryl ester), polyoxyethylene(20)sorbitan trioleate, Tween 20, Tween 80, vitamin E TPGS and mixtures of any of the two or more.The method for reducing GH levels or IGF-1 levels and/or treating an octreotide-sensitive disease involving a subcutaneous implantation of at least one dry implanted device comprising the declared preparation. The kit comprising the declared composition for octreotide controlled release.
EFFECT: group of inventions provides a therapeutically effective amount of octreotide for a long period of time with treating hormonal conditions.
25 cl, 11 ex, 7 tbl, 21 dwg
